Facebook Twitter

U.S. institute, Merck team up on HIV effort

SHARE U.S. institute, Merck team up on HIV effort

The National Institute of Allergy and Infectious Diseases, the leading HIV research agency of the U.S. government, has entered an agreement with Merck & Co. to collaborate on human testing of promising candidate HIV vaccines developed by the company.

The vaccines will be tested by the institute's international HIV Vaccine Trials Network, a group of more than 24 clinical sites worldwide established to move promising experimental HIV vaccines rapidly through all stages of human testing.

With an estimated 5 million new HIV infections worldwide this year, developing a vaccine is a top biomedical research priority, the institute said.